



 https://acBlood Pressure and Cardiac Autonomic Nervous
System in Obese Type 2 Diabetic Patients:
Effect of Metformin Administration
Daniela Manzella, Rodolfo Grella, Katherine Esposito,





niveBackground: Hyperinsulinemia/insulin resistance and
elevated plasma free fatty acids (FFA) levels are involved
in the hypertension and cardiac sympathetic overactivity.
Metformin improves insulin action and lower plasma FFA
concentrations. We investigate the possible effect of met-
formin on arterial blood pressure (BP) and cardiac sym-
pathetic nervous system.
Methods: One hundred twenty overweight type 2 dia-
betic patients were treated by placebo (n  60)  diet or
metformin (850 mg twice daily) (n  60)  diet for 4
months, to evaluate the effect of metformin treatment on
the cardiac autonomic nervous system. Insulin resistance
was measured by the Homeostasis Model Assessment
(HOMA) index. Heart rate variability (HRV) assessed
cardiac sympathovagal balance.
Results: Metformin treatment, but not placebo treat-
ment, was associated with a decrease in fasting plasma
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Published by Elsevier Inc.glucose (P  .05), insulin (P  .05), triglyceride (P 
.05), and FFA (P  .03) concentrations and HOMA index
(P  .03). Metformin treatment was also associated with
a significant improvement in cardiac sympathovagal bal-
ance but not in mean arterial BP. Furthermore, in a mul-
tivariate analysis, delta change in sympathovagal balance
index (LF/HF ratio) were associated with delta change in
plasma FFA concentrations and HOMA index indepen-
dently of gender and delta change in plasma triglyceride
and HbA1c concentrations.
Conclusions: Our study demonstrated that metformin
treatment might be useful for improving cardiac sympa-
thovagal balance in obese type 2 diabetic patients. Am J
Hypertens 2004;17:223–227 © 2004 American Journal of
Hypertension, Ltd.
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ber 2018I t is widely accepted that hyperinsulinemia/insulinresistance increases cardiovascular mortality in type2 diabetic patients due to sympathetic overactiv-
ity.1,2 Some recent data have also provided evidence that
elevated plasma-free fatty acid (FFA) concentration
causes a stimulation of the cardiac autonomic nervous
system and thus also has a proarrhythmic role.3,4 Because
metformin improves insulin action and lowers plasma
FFA concentrations one cannot rule out that metformin
could also affect the cardiac autonomic nervous system.
On the other hand, a direct effect of metformin on
sympathetic nervous activity has been demonstrated by the
ability of the drug to interrupt neurotransmission in sym-
pathetic ganglia.5 Thus, it is possible to hypothesize that
chronic metformin treatment in insulin resistant type 2
diabetic patients might be associated with a lowering of
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of the sympathovagal balance by an indirect (decline in
plasma FFA and or in insulin resistance) and by a direct
effect on the cardiac autonomic nervous system.
To the best of our knowledge no study has addressed
such a possibility in humans. Accordingly, we investigated
the possible effect of metformin versus placebo treatment
on cardiac autonomic nervous activity, assessed by heart
rate variability (HRV),6 in 120 overweight type 2 diabetic
patients (64 men/56 women).
Methods
One hundred twenty overweight type 2 diabetes mellitus
outpatients in treatment with only diet volunteered for the
study. All patients had no evidence of coronary heart
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ber 2018disease as confirmed by electrocardiogram, echocardiog-
raphy, and treadmill test. Furthermore, all patients under-
went Ewing tests7 to exclude the occurrence of diabetic
neuropathy. More detailed characteristics of patients are
given in Table 1. After clear explanation of potential risks
of the study, each volunteer gave written informed consent
to participate in the study, which was approved by the
Ethical Committee of our Institution.
Study Protocol
The study was designed as a randomized parallel group
trial of placebo  diet versus metformin  diet. At base-
line all patients were studied at 8:00 AM, in a quiet com-
fortable room at a temperature ranging between 22° and
24°C, after an overnight fast (at least 12 h). A venous
blood sample for plasma metabolites was immediately
drawn. Then, each patient rested in the supine position for
at least 30 min before starting baseline Holter recording,
which lasted 60 min. Then, all patients were randomly
assigned to placebo (n  60) or metformin treatment at a
dose of 850 mg twice daily (Metforal, Guidotti, Italy; n 
60). Each treatment lasted 4 months. At the end of this
treatment period, a complete reevaluation of the patients
was made.
Diet
All patients consumed a weight-stable diet (1500 kcal)
of carbohydrate (50%), fat (25%), and protein
(25%). The polyunsaturated-to-saturated fatty acids ratio
was 1.0. The amount of fiber in the diet was 10 g/d. The
patients were encouraged not to eat additional foods.
Anthropometric Determinations
Weight and height were measured using a standard tech-
nique. Body mass index (BMI) was calculated as body
weight (in kilograms)/height (meters squared). Waist cir-
cumference was measured at the midpoint between the
Table 1. Clinical characteristics of study groups at
metformin (n  60)
Baseline P
Gender (M/F) 33/27
BMI (kg/m2) 29.2  0.2 NS
WHR 0.92  0.35 NS
Glucose (mmol/mL) 8.3  0.9 NS
Insulin (pmol/mL) 83.4  2.9 NS
Triglycerides (mmol/L) 2.27  0.2 NS
Free fatty acids (mmol/L) 660  49 NS
HbA1c (%) 8.1  0.2 NS
HOMA index 3.97  0.15 NS
All results are mean  SD.
BMI  body mass index; WHR  waist hip ratio.
All parameters are considered at fasting condition.
Homeostasis assessment model (HOMA). No difference were fo
Placebo versus metformin: * P  .05; † P  .03.lower rib margin and the iliac crest (normally the umbil-ical level), and hip circumference was measured at the
trocanter level. Both circumferences were measured at the
nearest 0.5 cm with plastic tape and the ratio between them
provided the waist/hip ratio. The anthropometric measure-
ments are used because the change in body composition
may significantly affect both insulin resistance and cardiac
autonomic nervous activity. Thus, because our study
lasted 4 months, one could also hypothesize that changes
in HRV parameters and insulin resistance degree might
depend on the changes in body composition.
HOMA Index
Insulin resistance was assessed by the Homeostasis Model
Assessment (HOMA).8 HOMA is a mathematical model
describing the degree of insulin resistance starting from
patient’s fasting plasma insulin and glucose concentra-
tions.8 The accuracy and precision of the HOMA method
have been compared with independent estimates of insulin
resistance.8
Data Acquisition and Analysis
The software used for data acquisition and analysis has
been previously described.9,10 In brief, the computer pro-
gram first calculates the interval thacogram. From a sec-
tion of thacogram of 512 interval values, simple statistics
(mean and variance) are calculated. The computer pro-
gram automatically calculates the autoregressive coeffi-
cients necessary to define the power spectral density
estimate and prints out the power and frequency of each
spectral component. Two major oscillatory components
are usually detectable: 1) HF (0.25 Hz and varying with
respiration) is synchronous with respiration; 2) corre-
sponding to the slow waves of arterial pressure, LF (0.1
Hz). Each spectral component is presented in normalized
form (normalized units [nu]), by dividing it by the total
power minus the direct current component, if present.
Only components 5% of total power were considered
eline and after treatment with placebo (n  60) or
lacebo Baseline P Metformin
31/29
.5  0.4 29.5  0.1 NS 29.1  0.2
2  0.26 0.94  0.31 NS 0.89  0.14
.2  0.3 8.2  0.5 .05 7.3  0.2
.2  1.5 82.4  2.1 .05 66.1  1.3†
0  0.11 2.22  0.4 .05 1.94  0.15*
1  57 664  45 .03 556  42†
.9  0.3 8.0  0.2 .05 7.2  0.1*
5  0.12 4.02  0.14 .03 3.01  0.11†
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ber 2018a period of 2 min before the test. Subjects with a respira-
tory rate less than 10 breaths/min (ie, 0.15 Hz) were
excluded from the study. The LF/HF ratio is considered an
index of cardiac sympathetic/parasympathetic tone bal-
ance.6,11,12
Analytical Techniques
Plasma glucose concentrations were determined by the
glucose oxidative methods (glucose autoanalyzer, Beck-
man Coulter, Inc., Fullerton, CA). Plasma insulin concen-
trations were determined by radioimmunoassay (Linco
Research, Inc., St. Charles, MO). Plasma fasting triglyc-
eride concentrations were determined by routine labora-
tory methods. Plasma fasting FFA concentrations were
measured according to Miles et al.13 Stable HbA1 levels
were determined in triplicate according to Compagnucci et
al14 by ion-exchange microcolumns at constant tempera-
ture (18°C).
Statistical Analyses
All results are mean  SD. Mean arterial blood pressure
(BP) was calculated as diastolic BP plus one-third pulse
pressure. Changes in HbA1c, triglycerides, HOMA index,
and LF/HF ratio are used only to compare the changes
(and not just the absolute values) of these variables. Be-
cause of the skewed distribution, total power, LF, HF,
plasma insulin, triglyceride, FFA concentrations, and
HOMA index were logarithmically transformed for statis-
tical testing and back transformed for presentation in table.
Analysis of variance (ANOVA) allowed calculating dif-
ference between the two study groups. Multivariate regres-
sion analysis tested the independent association and
contribution of gender,  changes in HOMA index,
plasma FFA, triglyceride, and HbA1c levels with the
dependent variable (LF/HF ratio). A P value of .05 was
chosen as the level of significance. All calculations were
made on an IBM personal computer by SPSS 10.0 (SPSS,
Chicago, IL).
Results
All volunteers completed the study. All patients were
Table 2. Cardiovascular parameters of study group
or metformin (n  60)
Baseline P
MABP (mm Hg) 110  1.6 NS
RR interval (msec) 759  12 NS
Total power (msec2) 2744  296 NS 2
LF (nu) 70.1  1.6 NS 6
HF (nu) 22.5  1.6 NS 2
LF/HF ratio 4.8  0.2 NS
All results are mean  SD.
MABP  mean arterial blood pressure; LF  low frequency; HF 
No differences were found between the two groups at baselineadults (age, 5711 years) and nonsmokers (Table 1). Atbaseline anthropometric and metabolic parameters were
similar in both study groups. At the end of study, met-
formin, but not placebo administration, was associated
with a significant decrease in fasting plasma glucose,
insulin, triglyceride, FFA, and HbA1c concentrations, as
well as in insulin resistance (HOMA) (Table 1). With
regard to cardiovascular parameters (Table 2), both groups
had similar values at baseline. Mean arterial BP was
unaffected by both treatment modes. In contrast, met-
formin versus placebo, had a strong impact on HRV pa-
rameters. In fact, an increase in RR interval, total power,
and HF, and a decrease in LF and LF/HF ratio were found
after metformin administration (Table 2).
Due to the occurrence of statistically significant differ-
ences in plasma HbA1c, triglyceride, and FFA concentra-
tions, HOMA index and LF/HF ratio before and after
metformin treatment, delta () changes in these param-
eters were calculated. Thus, a multivariate analysis was
made using these parameters. In such analysis LF/HF ratio
was the dependent variable, whereas gender,  changes in
HOMA index, plasma FFA, triglyceride, and HbA1c lev-
els were the independent variables. Such a model ex-
plained 73% of the variability in the  changes in the
LF/HF ratio with  changes in plasma FFA level (t 
2.65; P  .01) and HOMA index (t  2.42; P  .03)
independently and significantly associated with  changes
in the LF/HF ratio. Furthermore, percentage changes in
plasma FFA and HOMA index explained 26% and 18% of
the LF/HF ratio variability, respectively. Only 5 patients
had minor gastrointestinal symptoms, such as side effects
of metformin administration.
Discussion
Our results demonstrate that the metformin-related de-
crease in plasma FFA and insulin resistance is associated
with an improvement in cardiac autonomic nervous bal-
ance in overweight type 2 diabetic patients.
Type 2 diabetic patients are characterized by a greater
increased cardiac mortality than healthy subjects.15
Among the factors responsible for such elevated mortality,
hyperinsulinemia/insulin resistance and high plasma FFA
baseline and after treatment with placebo (n  60)
cebo Baseline P Metformin
 1.2 112  1.8 NS 108  2.9
 10 758  10 .05 866  12*
 312 2711  395 .05 2915  348*
 1.3 68.6  1.5 .05 52.1  1.1*
 1.8 22.4  1.8 .05 23.6  2.1*
 0.3 4.7  0.3 .02 2.9  0.2†
h frequency.
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theless, the underlying mechanisms responsible for such
sympathetic overactivity are not fully understood. In hu-
mans, the relationship between hyperinsulinemia and sym-
pathetic activity seems strengthened by measurements of
plasma cathecolamine concentrations,19 plasma norepi-
nephrine spillover,20 direct microneurographic recordings
of sympathetic nerve action,21 and also by evaluation of
cardiac autonomic activity studied by HRV technique.9,22
In particular, it has been demonstrated that acute infusion
of insulin is associated with a significant increase in car-
diac sympathetic activity in healthy subjects9 and in pa-
tients affected by insulin resistance.22 An impact of insulin
on the central nervous system has been hypothesized, as
insulin crosses the blood–brain barrier, and the insulin
receptor has been demonstrated in several distinct regions
of the central nervous system such as the median hypo-
thalamus.23
The relationship between plasma FFA concentrations
and the autonomic nervous system was suggested by Bu-
low et al24 showing a vasoconstriction secondary to local
perfusion of adipose tissue with FFA. Later, Stepnia-
kowski et al25 reported that infusion of lipid emulsion plus
heparin reduced vein distensibility in healthy volunteers
and increased responsiveness to phenylephrine. Grekin et
al26 reported that portal FFA infusion also has significant
pressor effects, which may be mediated by increased sym-
pathetic tone. We also showed that elevated plasma FFA
concentrations per se might stimulate the cardiac sympa-
thetic nervous system in healthy subjects4 and in type 2
diabetic patients.17 Recently we demonstrated that in-
creased postprandial FFA concentrations are associated
with an increase in oxidative stress and a neural pressor
response, which have a negative impact on sympathetic
and parasympathetic balance.18
The effect of metformin on insulin resistance27 and
plasma FFA concentrations28 has been experimentally
supported. In particular, Abbasi et al28 have demonstrated
that FFA concentrations were lower after metformin treat-
ment, and suggested that metformin can act on the adipose
tissue decreasing FFA release, which, in turn, results in a
decline of circulating FFA concentrations. These events
should enhance muscle glucose disposal. Due to the strong
relationship occurring between insulin resistance/hyperin-
sulinemia and sympathetic nervous system overactivity,
metformin administration could bring down the sympa-
thetic overactivity observed in our patients.
To the best of our knowledge we are the first to evaluate
such an effect of metformin on cardiac autonomic nervous
activities, which seems related to a decrease in plasma
FFA concentrations and insulin resistance (HOMA). In
fact, in our study, the multivariate analysis showed that
changes in plasma FFA concentration and in HOMA index
were associated with a change in LF/HF ratio indepen-
dently of gender and of the changes in plasma triglyceride
and HbA1c levels.It should be pointed out that an additional effect ofmetformin might be due to a direct effect on the sympa-
thetic nervous activity. Actually, this effect has been dem-
onstrated only in an experimental model. In particular,
Santure et al29 suggested that, in spontaneous hypertensive
rats, part of the beneficial effect of metformin on insulin
resistance results from a potentiation of the hormone-
stimulating effect on glucose transport in peripheral tis-
sues. Petersen and Di Bona30 have shown that metformin
decreases BP, heart rate, and efferent renal sympathetic
nerve activity after intracerebroventricular administration.
Thus, they concluded that metformin has acute sympa-
thoinibitory effects produced by a direct central system site
of action. Unfortunately, our study design was not appro-
priate to investigate the potential effect of metformin per
se on arterial BP and cardiac autonomic nervous system
and thus, we cannot rule out or confirm such an effect on
humans. Nevertheless, even if there is a limitation in our
study with regard to HRV on sympathetic cardiovascular
control, there is great interest in investigating the sympa-
thovagal balance alteration, especially in relation to the
unexpected sudden deaths, in diabetic patients. Thus, a
HRV test seem to be an appropriate test to be used in our
study.
In conclusion, our study demonstrated that metformin-
related changes in plasma FFA and in insulin resistance
may be useful to improve autonomic nervous system bal-
ance at the cardiac level but not arterial BP in overweight
type 2 diabetic patients.
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